MétaCan
Menu
Back to cohort
Record W4409296071 · doi:10.1158/2159-8290.cd-24-1726

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements

2025· article· en· W4409296071 on OpenAlexaff
Seshiru Nakazawa, Federica Pecci, Igor Odintsov, Dimitris Gazgalis, Felix H. Gottlieb, Biagio Ricciuti, Lodovica Zullo, Joao V. Alessi, Alessandro Di Federico, Mihaela Aldea, Edoardo Garbo, Malini Gandhi, Arushi Saini, William W. Feng, Jie Jiang, Simon Baldacci, Francesco Facchinetti, Maisam Makarem, Marie-Anaïs Locquet, Koji Haratani, Danielle Haradon, Benjamin Besse, Antoîne Italiano, Jordi Remón, Pernelle Lavaud, Damien Vasseur, David Planchard, Yusuke Sato, Y. Watanabe, Scott Owen, Alexis B. Cortot, Hoda A. Mahran, Martin Förster, Jiaxin Niu, Pascale Tomasini, Leong Swan Swan, Kevin Tay, Emilio Esteban, Anna Minchom, Sani H. Kizilbash, Marcia Cruz‐Correa, Kin-Hung P. Yu, Pan Chen, Mythili Sangem, Jianwei Che, Lynette M. Sholl, Pasi A. Jänne, Mark M. Awad

Bibliographic record

VenueCancer Discovery · 2025
Typearticle
Languageen
FieldMedicine
TopicLiver physiology and pathology
Canadian institutionsMcGill University Health Centre
FundersNational Cancer InstituteApollomicsAmerican Cancer Society
KeywordsCancer researchFusion geneLung cancerAdenocarcinomaCancerBiologyTyrosine kinaseExonMedicineGeneOncologyInternal medicineGeneticsSignal transduction

Abstract

fetched live from OpenAlex

Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumor activity of MET inhibitors in MET rearrangement-positive cancers are limited. In this study, in a pan-cancer analysis of >46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic MET rearrangements in ∼0.04% of cancers. Preliminary analysis from a phase II clinical trial of the type I MET tyrosine kinase inhibitor (TKI) vebreltinib in MET fusion-positive solid tumors demonstrated an objective response rate of 50% and disease control rate of 79%, with antitumor activity seen in diverse cancer types, including lung adenocarcinoma and intrahepatic cholangiocarcinoma, among others. Similar to MET exon 14-altered lung cancer, secondary mutations in the kinase domain can confer resistance to MET TKIs in MET fusion-positive cancers. Overall, these data categorize MET rearrangements as actionable targets in solid tumors. SIGNIFICANCE: MET rearrangement-positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.417
Threshold uncertainty score0.225

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.305
Teacher spread0.293 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCancer DiscoverySame topicLiver physiology and pathologyFrench-language works237,207